Preserved C-reactive protein responses to blood stream infections following tocilizumab treatment for COVID-19
Abstract C-reactive protein (CRP) levels are elevated following bacterial infections but may be attenuated by the IL-6-receptor antagonist tocilizumab. In hospitalised COVID-19 patients, tocilizumab induced a transient (<21 day) fall in CRP but retained CRP responses to nosocomial blood stream infections, and therefore its utility in guiding antibiotic prescribing..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 05. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wey, Emmanuel Q [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2021.07.03.21259949 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI032156707 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI032156707 | ||
| 003 | DE-627 | ||
| 005 | 20231205150331.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210709s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.07.03.21259949 |2 doi | |
| 035 | |a (DE-627)XBI032156707 | ||
| 035 | |a (biorXiv)10.1101/2021.07.03.21259949 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wey, Emmanuel Q |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preserved C-reactive protein responses to blood stream infections following tocilizumab treatment for COVID-19 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract C-reactive protein (CRP) levels are elevated following bacterial infections but may be attenuated by the IL-6-receptor antagonist tocilizumab. In hospitalised COVID-19 patients, tocilizumab induced a transient (<21 day) fall in CRP but retained CRP responses to nosocomial blood stream infections, and therefore its utility in guiding antibiotic prescribing. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Bristow, Clare |4 aut | |
| 700 | 1 | |a Nandani, Aarti |4 aut | |
| 700 | 1 | |a O’Farrell, Bryan |4 aut | |
| 700 | 1 | |a Pang, Jay |4 aut | |
| 700 | 1 | |a Lanzman, Marisa |4 aut | |
| 700 | 1 | |a Yang, Shuang |4 aut | |
| 700 | 1 | |a Ho, Soo |4 aut | |
| 700 | 1 | |a Mack, Damien |4 aut | |
| 700 | 1 | |a Spiro, Michael |4 aut | |
| 700 | 1 | |a Balakrishnan, Indran |4 aut | |
| 700 | 1 | |a Bhagani, Sanjay |4 aut | |
| 700 | 1 | |a Pollara, Gabriele |0 (orcid)0000-0001-5772-0322 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 05. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:05 |g month:11 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jinf.2021.08.017 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.07.03.21259949 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 05 |c 11 | ||